US 12,447,178 B2
Method of treatment using anti-CD19 rituximab-resistant chimeric antigen receptors
Thomas Charles Pertel, San Mateo, CA (US); Barbra Johnson Sasu, San Francisco, CA (US); and Mark W. Leonard, Burlingame, CA (US)
Assigned to Allogene Therapeutics, Inc., South San Francisco, CA (US)
Filed by ALLOGENE THERAPEUTICS, INC., South San Francisco, CA (US)
Filed on Dec. 26, 2023, as Appl. No. 18/395,996.
Application 18/395,996 is a division of application No. 16/857,573, filed on Apr. 24, 2020, granted, now 11,896,617.
Claims priority of provisional application 63/005,041, filed on Apr. 3, 2020.
Claims priority of provisional application 62/839,455, filed on Apr. 26, 2019.
Prior Publication US 2024/0277763 A1, Aug. 22, 2024
Int. Cl. A61K 39/395 (2006.01); A61K 35/17 (2015.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01); C12N 15/00 (2006.01)
CPC A61K 35/17 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); A61P 35/00 (2018.01); C07K 14/70517 (2013.01); C07K 14/70596 (2013.01); C07K 16/2803 (2013.01); C12N 5/0636 (2013.01); A61K 2039/505 (2013.01); A61K 2239/38 (2023.05); C07K 2317/76 (2013.01); C07K 2319/33 (2013.01); C12N 2510/00 (2013.01); C12N 2740/15043 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A method of treating a CD19-expressing cancer or malignancy in a subject in need thereof comprising administering to the subject an engineered immune cell that comprises an isolated polynucleotide encoding a polypeptide comprising an anti-CD19 chimeric antigen receptor (CAR) that comprises the amino acid sequence of SEQ ID NO: 9, wherein the polypeptide does not comprise a rituximab binding site, wherein the polynucleotide comprises a nucleic acid sequence having at least 90% identity to SEQ ID NO: 3 and a short EF1a promoter that is capable of expressing the anti-CD19 chimeric antigen receptor (CAR) in a mammalian T cell, and wherein the short EF1a promoter comprises the nucleic acid sequence of SEQ ID NO:16 and does not comprise the nucleic acid sequence of SEQ ID NO:39.